HK1211495A1 - 用於治療與 依賴的補體活化相關的疾病的方法 - Google Patents

用於治療與 依賴的補體活化相關的疾病的方法

Info

Publication number
HK1211495A1
HK1211495A1 HK15112489.6A HK15112489A HK1211495A1 HK 1211495 A1 HK1211495 A1 HK 1211495A1 HK 15112489 A HK15112489 A HK 15112489A HK 1211495 A1 HK1211495 A1 HK 1211495A1
Authority
HK
Hong Kong
Prior art keywords
masp
methods
conditions associated
complement activation
treating conditions
Prior art date
Application number
HK15112489.6A
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Cordula M Stover
Clark E Tedford
James B Parent
Teizo Fujita
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of HK1211495A1 publication Critical patent/HK1211495A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15112489.6A 2004-06-10 2015-12-18 用於治療與 依賴的補體活化相關的疾病的方法 HK1211495A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57884704P 2004-06-10 2004-06-10

Publications (1)

Publication Number Publication Date
HK1211495A1 true HK1211495A1 (zh) 2016-05-27

Family

ID=35355643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112489.6A HK1211495A1 (zh) 2004-06-10 2015-12-18 用於治療與 依賴的補體活化相關的疾病的方法

Country Status (16)

Country Link
US (1) US20060002937A1 (zh)
EP (15) EP2465534B1 (zh)
CN (2) CN104721824A (zh)
AU (1) AU2005254044B2 (zh)
CA (4) CA2573144C (zh)
CY (3) CY1125022T1 (zh)
DK (3) DK2465534T3 (zh)
ES (4) ES2601497T3 (zh)
HK (1) HK1211495A1 (zh)
HU (3) HUE032349T2 (zh)
LT (3) LT2465534T (zh)
PL (3) PL2446900T3 (zh)
PT (3) PT1753456T (zh)
SI (2) SI2446900T1 (zh)
TR (1) TR201708554T4 (zh)
WO (1) WO2005123128A2 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
PT1625166E (pt) 2003-05-12 2015-08-20 Helion Biotech Aps Anticorpos para masp-2
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2006214320C1 (en) 2005-02-14 2012-07-05 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8524453B2 (en) * 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
JP2009538279A (ja) * 2006-03-09 2009-11-05 ユニバーシティー オブ ロチェスター 末梢および神経の炎症性クロストーク
WO2008007159A1 (en) * 2006-07-14 2008-01-17 Eötvös Lorand University Measurement of complement activation products on antigen arrays
US7723292B2 (en) * 2006-09-06 2010-05-25 Fernando And Anna Foundation Compositions and methods for treating cancer
US9278201B2 (en) 2009-06-15 2016-03-08 Perflow Medical Ltd. Method and apparatus for allowing blood flow through an occluded vessel
EP3395828A1 (en) * 2009-07-17 2018-10-31 Rigshospitalet Inhibitors of complement activation
PL2488203T3 (pl) * 2009-10-16 2017-08-31 Omeros Corporation Sposoby leczenia rozsianego wykrzepiania wewnątrznaczyniowego przez hamowanie aktywacji dopełniacza zależnej od masp-2
AU2013201443B2 (en) * 2009-10-16 2015-02-05 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2015271989B2 (en) * 2011-04-08 2017-09-21 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3287142B1 (en) * 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
AU2013201627B2 (en) * 2011-04-08 2016-02-11 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107011443B (zh) 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
SI2861246T1 (sl) * 2012-06-18 2021-08-31 Omeros Corporation Kompozicije in postopki za zaviranje MASP-1 in/ali MASP-2 in/ali MASP-3 za zdravljenje različnih bolezni in bolezenskih stanj
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
AU2013337638B2 (en) 2012-11-02 2018-10-25 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
GB201314452D0 (en) * 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
IL283373B2 (en) * 2013-10-17 2024-08-01 Omeros Corp Pharmaceutical preparations containing substances that suppress MASP-2 to suppress complement activation that depends on MASP-2 and related diseases
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
JP7005483B2 (ja) 2015-04-06 2022-02-10 バイオベラティブ ユーエスエー インコーポレイテッド ヒト化抗Ｃ１ｓ抗体及びその使用方法
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
KR20190128674A (ko) * 2017-03-09 2019-11-18 쿄와 기린 가부시키가이샤 Masp2의 발현을 억제하는 핵산
BR112020024148A2 (pt) * 2018-05-29 2021-03-30 Omeros Corporation Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
CN110833624B (zh) * 2018-08-16 2021-11-12 中国人民解放军军事科学院军事医学研究院 α1-AT表达载体在制备输血相关急性肺损伤保护剂中的应用
EP3849304B1 (en) * 2018-09-13 2024-01-10 Regeneron Pharmaceuticals, Inc. Complement factor h gene knockout rat as a model of c3 glomerulopathy
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
PE20220431A1 (es) 2019-05-07 2022-03-29 Bayer Ag Compuestos inhibidores de la masp y usos de estos
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
CN111830254B (zh) * 2020-07-29 2022-07-26 武汉生之源生物科技股份有限公司 一种基质金属蛋白酶-3测定试剂盒及其制备方法
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
US20240010684A1 (en) 2020-11-04 2024-01-11 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN113016721A (zh) * 2021-03-29 2021-06-25 何冬凌 中华眼镜蛇咬伤猪模型的制备及用途
CN116981477A (zh) * 2021-04-25 2023-10-31 江苏恒瑞医药股份有限公司 抗masp2抗体、其抗原结合片段及医药用途
CN114747535B (zh) * 2022-03-29 2024-03-22 华南理工大学 一种急性脓毒症非人灵长类动物模型及其构建方法
WO2024026258A2 (en) * 2022-07-25 2024-02-01 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
WO2024140939A2 (zh) * 2022-12-29 2024-07-04 苏州创胜医药集团有限公司 含有治疗性抗体的药物制剂及其用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPS60211522A (ja) * 1984-04-05 1985-10-23 Kubota Ltd 作業車の操作構造
GB8412632D0 (en) * 1984-05-17 1984-06-20 Atomic Energy Authority Uk Corrosion monitoring probe
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
EP2322226A3 (en) 1999-07-21 2011-08-17 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DE60139072D1 (de) * 2000-07-13 2009-08-06 Helion Biotech Aps Masp-2, ein komplement fixierendes enzym, und dessen verwendungen
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
WO2003063799A2 (en) 2002-02-01 2003-08-07 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU2003223288A1 (en) * 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
US20060275764A1 (en) * 2002-12-03 2006-12-07 Aarhus Universitet Method for determining predisposition to manifestation of immune system related diseases
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
PT1625166E (pt) * 2003-05-12 2015-08-20 Helion Biotech Aps Anticorpos para masp-2
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells

Also Published As

Publication number Publication date
LT2446900T (lt) 2017-07-25
EP3530288A3 (en) 2019-12-18
LT2465534T (lt) 2017-07-25
DK2446900T3 (en) 2017-07-10
SI2446900T1 (sl) 2017-08-31
EP1753456A2 (en) 2007-02-21
WO2005123128A2 (en) 2005-12-29
EP2465534B1 (en) 2017-03-29
EP2386316A1 (en) 2011-11-16
CA2847677C (en) 2018-05-01
AU2005254044A1 (en) 2005-12-29
EP2457585A1 (en) 2012-05-30
ES2601497T3 (es) 2017-02-15
CA2573144C (en) 2014-07-22
ES2671052T3 (es) 2018-06-04
HUE033239T2 (hu) 2017-11-28
EP2446902A1 (en) 2012-05-02
ES2628867T3 (es) 2017-08-04
CA2998633C (en) 2021-01-26
EP2446901A1 (en) 2012-05-02
PL2465534T3 (pl) 2017-08-31
EP2465535A1 (en) 2012-06-20
AU2005254044B2 (en) 2011-09-29
CN104721824A (zh) 2015-06-24
PL1753456T3 (pl) 2017-01-31
CA2847677A1 (en) 2005-12-29
EP3530288A2 (en) 2019-08-28
EP2386317A1 (en) 2011-11-16
PT2446900T (pt) 2017-06-28
EP2386315A1 (en) 2011-11-16
EP2392350A1 (en) 2011-12-07
US20060002937A1 (en) 2006-01-05
EP2465534A1 (en) 2012-06-20
PL2446900T3 (pl) 2017-09-29
CA2573144A1 (en) 2005-12-29
PT2465534T (pt) 2017-06-27
DK2465534T3 (en) 2017-07-03
CY1119343T1 (el) 2018-02-14
EP2386316B1 (en) 2018-02-28
CA3102252A1 (en) 2005-12-29
WO2005123128A3 (en) 2007-01-25
EP1753456B1 (en) 2016-08-10
EP2460537A1 (en) 2012-06-06
TR201708554T4 (tr) 2019-02-21
CY1119339T1 (el) 2018-02-14
EP2446900A1 (en) 2012-05-02
CA2998633A1 (en) 2005-12-29
EP2382991A1 (en) 2011-11-02
LT1753456T (lt) 2016-11-10
CN101018565A (zh) 2007-08-15
ES2631127T3 (es) 2017-08-28
HUE029437T2 (en) 2017-02-28
CY1125022T1 (el) 2022-07-22
PT1753456T (pt) 2016-11-04
EP3047858A1 (en) 2016-07-27
SI2465534T1 (sl) 2017-08-31
DK1753456T3 (en) 2016-11-28
HUE032349T2 (en) 2017-09-28
EP2446900B1 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
HK1211495A1 (zh) 用於治療與 依賴的補體活化相關的疾病的方法
DK3067067T3 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
IL180645A0 (en) Methods for treating hepatitis c
IL186895A0 (en) Methods for treating eye conditions
ZA200705459B (en) Treatment method
EP1827450A4 (en) METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
PL1793842T3 (pl) Leczenie zespołu zmęczenia w chorobie nowotworowej
GB0506759D0 (en) Combination treatment methods
EP1732707A4 (en) ACTIVATION METHOD
ZA200607115B (en) Permanent treatment method
IL176829A0 (en) Composition for treating pathology associated with msrv/herv-w
EP1737676A4 (en) PROCESS FOR PREVENTING EDGE CURING
LT2392336T (lt) 24-norudca, skirta autoimuninio hepatito gydymui
EP1809276A4 (en) PROCESSING PROCESS
ZA200701235B (en) Methods for treating hepatitis C
GB0426141D0 (en) Treatment
AU2013201564B2 (en) Methods for treating conditions associated with MASP-2-dependent complement activation
GB2413132B (en) Balsams for treating leather
GB0406103D0 (en) Treatment method
IL162179A0 (en) Enhancement for cvt
GB0412411D0 (en) Treatment